Citations

Clear

4847 citation(s) found for "Yu, Eric".

Abstract 17686: Appropriate Use and Clinical Impact of Early Echocardiograms in Hospitalized Patients
Kadkhodayan, Ana, Dailey, Eric J. , Buechler, Tamara, Newman, James S. , Chiriac, Anca Eduard , Pislaru, Sorin V. , Pellikka, Patricia A.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 130 | Issue: suppl_2 | Pages: No page available

10.1161/circ.130.suppl_2.17686 Get It

Introduction: Transthoracic echocardiography (TTE) is a versatile tool for investigating cardiac function in hospitalized patients, but it was recently suggested that only a fraction of the studies result in an active change in management. The importance of early inpatient TTE to guide management and rule out important alternative pathology has not been previously investigated. The opinion of the referring provider has never been systematically surveyed. Hypothesis: Appropriate use (AU) of TTE in hospitalized patients has significant implications for patient care, even without resulting in direct alterations in management. Methods: We conducted a prospective review of 546 consecutive echocardiograms performed within 72 hours of hospital admission. An electronic survey consisting of 6 questions pertinent to rationale for TTE and consequences to patient care was sent to physicians. AU was independently determined by two investigators blinded to survey results and clinical outcomes, with differences adjudicated by a third independent investigator. Results: Of 546 TTEs included in this study, 526 (96%) were appropriate, 2% inappropriate, and 2% uncertain. Although only 48% of responders actively changed management after TTE results, 97% thought the TTE answered their clinical question. At least one new medication change occurred in 190 (35%) patients. Moreover, 95% of physicians would do another TTE in a similar situation, either to guide cardiac therapy, rule out contributing cardiac pathology, or support their current therapeutic plan. Only 5% of responders would not order another TTE if given a similar presentation in the future. Furthermore, our study uncovered a high incidence of unexpected findings (33% of TTEs), ranging from new decrease in LV systolic function, new valvular dysfunction, to pericardial effusion and new aortic aneurysm. These findings have significant clinical implications for the individual patient. Conclusions: Most early inpatient TTEs at our institution were appropriate and answered a specific clinical question important for management decisions. Even those not directly altering the acute therapeutic strategy impacted clinical course. A large number of significant incidental findings were recorded.
Abstract 18338: Genomics-metabolomics Integrative Approach Reveals Novel Biomarkers In DPYS Associated With Higher Glucose Change After Treatment With Atenolol
Oliveira, Felipe A. de, Shahin, Mohamed H. , McDonough, Catrin W, Beitelshees, Amber L. , Chapman, Arlene B. , Boerwinkle, Eric , Gong, Yan , Gums, John G. , Turner, Stephen T. , Frye, Reginald F. , Fiehn, Oliver , Kaddurah‐Daouk, Rima , Johnson, Julie A. , Cooper‐DeHoff, Rhonda M.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.18338 Get It

Introduction: β-blockers, including atenolol, are among the most widely prescribed antihypertensive drug classes. However, their use has been associated with hyperglycemia and incident diabetes, which poses concern for prescribers and patients. The Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study is a multicenter clinical trial with one of its objectives to identify genetic influences on adverse metabolic events in patients treated with atenolol. Here we report a genomics-metabolomics integrative approach to identify biomarkers associated with atenolol-induced glucose change. Methods: PEAR participants were genotyped using the Illumina Omni 1M-Quad Chip. Metabolite profiles were acquired through GC-TOF-MS. Association between baseline levels of metabolites and glucose change was conducted using a multivariate linear regression model adjusted for age, gender and baseline fasting glucose. Genomics-metabolomics integration included selecting SNPs within genes involved in the synthesis and degradation of top metabolites and testing their effect on glucose change in 234 atenolol-treated Caucasians in PEAR, adjusting for age, gender, baseline glucose and principal components 1 and 2. A false discovery rate (FDR) of .05 was used to adjust for multiple comparisons. Replication of significant SNPs was conducted in an additional 228 participants treated with atenolol in PEAR. Results: Metabolomics analysis revealed 3 metabolites associated with glucose change that passed FDR adjustment. The top metabolite signal was beta-alanine. Increasing levels of baseline beta-alanine was significantly correlated with greater glucose increases after atenolol treatment (p=.0003). A total of 79 SNPs in 12 genes in the beta-alanine pathway were explored. SNP rs2669429 in DPYS was significantly associated with glucose change, after FDR adjustment. We found that G allele carriers had significantly greater glucose change compared with non-carriers (p=.0006; β=+2.76 mg/dL). This finding was successfully replicated in the other 228 patients who received atenolol (p=.04; β=+1.86 mg/dL). Conclusions: These results suggest that beta alanine and DPYS rs2669429 SNP might be an important predictor of atenolol-induced dysglycemia.
Abstract 17182: Patterns of Discontinuation for Non-vitamin K Oral Anticoagulants in Atrial Fibrillation: Results From the ORBIT-AF II Registry
Simon, DaJuanicia N., Thomas, Laine , Ansell, Jack , Kowey, Peter R. , Piccini, Jonathan P. , Steinberg, Benjamin A. , Gersh, Bernard J. , Fonarow, Gregg C. , Hylek, Elaine M. , Mahaffey, Kenneth W. , Peterson, Eric D.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.17182 Get It

Background: Oral anticoagulation (OAC) is effective at preventing stroke in patients with atrial fibrillation (AF), yet warfarin is often poorly tolerated. Non-vitamin K oral anticoagulants (NOACs) are as or more effective as warfarin, yet their tolerance and persistence in clinical practice is not known. Methods: We assessed patterns of persistent OAC use among 2,345 AF patients starting on therapy in the ORBIT-AF II registry (71% starting on a NOAC, and 29% on warfarin). Results: By 6 months, 364 (22%) patients started on a NOAC had discontinued or changed initial therapy versus 143 (21%) started on warfarin initially (p=0.5). Among warfarin users, patients who switched or discontinued therapy were of similar age (median ages 72 and 74 vs. 74 for stable users, p=0.7) and CHA2DS2-VASc scores (mean 98 and 3.66 vs. 3.84, p=0.4). Among NOAC users, those who discontinued treatment were younger (median age 68 vs. 73 for those who switched and 72 for stable users; p=0.0004), and lower CHA2DS2-VASc scores (3.02 vs. 3.58 and 3.47, respectively; p=0.0008). The median time to change or discontinuation was more rapid in those started on a NOAC vs warfarin (97 days vs. 122 days, p=0.003). Among those on warfarin at baseline, 7.6% (n=52) were switched to a NOAC within 6 months, whereas transitions from NOAC to warfarin was 2.5% (n=42).Transitions among NOACs occurred in 9.8%, 3.2%, and 5.5% of patients on baseline dabigatran, rivaroxaban, and apixaban, respectively. Physician preference was the most common reason for both OAC and warfarin changes (Table). Drug cost was the primary reason for change of therapy in 15% of NOAC users (vs. 0 for warfarin). Conclusions: At 6-month follow-up, one in five newly started on OAC had discontinued or changed. These rates of change were similar among warfarin and NOAC treated patients. Cost concerns drove discontinuation in a modest number of patients, however, cost concerns were more prevalent in NOAC-treated patients.
Abstract 17152: Frequency and Management of Major Bleeding in Atrial Fibrillation Patients Treated With Warfarin and Non-vitamin K Oral Anticoagulants in Community Practice: Results From the ORBIT-AF II Registry
Simon, DaJuanicia N., Thomas, Laine , Ansell, Jack , Kowey, Peter R. , Piccini, Jonathan P. , Steinberg, Benjamin A. , Fonarow, Gregg C. , Gersh, Bernard J. , Mahaffey, Kenneth W. , Peterson, Eric D.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.17152 Get It

Background: Non-vitamin K oral anticoagulants (NOACs) are effective at preventing stroke in patients with atrial fibrillation (AF). However, little is known about the frequency of major bleeds on NOACs and how these events are managed in clinical practice. Methods: We assessed the rates, management, and outcomes of ISTH major bleeding events among AF patients in the ORBIT-AF II registry (mean follow-up 213 days). Results: Overall, 103 patients experienced 110 major bleeding events during follow-up n=90/4986 (1.8%) on NOAC, and n=20/1320 (1.5%) on warfarin. Patients with bleeding events on NOAC were slightly younger than those on warfarin (median age 76 vs. 80; p=0.2). Among mutually-exclusive bleeding types, intracranial bleeding was more common in warfarin treated patients than NOAC-treated (15% vs 6.7%), whereas GI bleeding was more common on NOACs (56% vs. 40%, overall p=0.1 for bleeding type). Management of bleeding differed by anticoagulation type: blood products and reversal agents were more commonly used in patients on warfarin (Table). No patient received prothrombin complexes, recombinant factor VIIa, aminocaproic acid, tranexamic acid, aprotinin, or desmopressin. Out of 90 major bleeding events in NOAC patients, only 1 was fatal (1%). Within 30 days following bleeding, there were no strokes and 1 TIA (NOAC). Following a major bleed, the recurrent bleeding rate in NOAC patients in the next 30-days was 4% and the death rate was 4%. Conclusions: Rates of major bleeding with NOACs in clinical practice are comparable to those reported in clinical trials. Compared with warfarin, bleeding among NOAC users was less likely intracranial and more likely to be GI. Management of bleeding in the setting of NOAC rarely includes reversal agents.
Abstract 14332: Factors Associated With Quality of Life in Atrial Fibrillation: Results From the ORBIT-AF Registry
Randolph, Tiffany C., Simon, DaJuanicia N., Kowey, Peter R. , Reiffel, James A. , Piccini, Jonathan P. , Fonarow, Gregg C. , Gersh, Bernard J. , Naccarelli, Gerald V. , Chan, Paul S. , Spertus, John A. , Peterson, Eric D.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.14332 Get It

Background: With increasing options for treating atrial fibrillation (AF), it is important to understand and quantify patient symptoms and quality of life (QoL), as improving symptoms and maximizing QoL are primary treatment goals. However, little is known about the factors associated with QoL. Methods: The Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) is a disease-specific QoL tool for AF, with domain and summary scores ranging from 0 (the worst health status) to 100. Using hierarchical pseudo-binomial regression, we evaluated factors associated with baseline AFEQT Summary and Subscale scores in the ORBIT AF registry. Adjusted associations were reported as odds ratios (OR) and 95% confidence intervals (CI). Results: AFEQT was assessed in 2,007 AF outpatients from 99 sites. Median age and interquartile range (IQR) was 76 (67-82); 43% were female; and the median CHA2DS2-VASC score was 4 (3-5). Median AFEQT summary score was 82 (67, 94). Median symptom score was 92 (78-100) and daily activity score was 77 (52-94). Female sex, younger age, new onset AF, higher heart rate, obstructive sleep apnea, and CAD were all associated with reduced QoL. (Table) Similar trends were seen for the symptoms subscale: female sex [OR 0.57 CI (0.48, 0.68)], younger age [OR 1.10 CI (1.06, 1.15)], and new onset AF [OR 0.55 CI (0.43, 0.70)] were associated with worse symptoms. Likewise, for the daily activities subscale, Other race [OR 0.54 CI (0.36-0.80)] and higher BMI [OR 0.98 CI (0.98-0.99)] were associated with decreased activity. Conclusions: In the largest community-based assessment of QoL in patients with AF, we found several patient factors to be associated with low QoL, including female sex, new onset AF, younger age, higher heart rate, and certain cardiopulmonary comorbidities. Understanding patient characteristics associated with worse QoL can be a foundation for eradicating disparities and tailoring treatment.
Abstract 3229: First Time Validation of Point to Point NavX Map Registration to 3D Subject-Specific Computed Tomography (CT)
Kolasa, Mark, Johnson, Susan B., Olson, Eric, Schweitzer, Jeffrey S. , Packer, Douglas L. , Okumura, Yasuo , Schweitzer, Jeffrey

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_726-c Get It

Background: Current mapping systems use simultaneous displays of overlapping 3D maps and pre-acquired CT images of the LA to “pseudo-register” data sets rather than specifically “register” each point of one mapping data set to the other. The appropriateness of the 2 data set match has not been validated. Since significant surface to surface mismatch errors may occur, this study was undertaken to quanititatively validate NavX map to CT registration and determine its suitability for guiding AF ablation. Methods: Sixty-four slice, multidetector CT scans were acquired in 8 dogs and segmented to establish subject-specific LA/PV volumes for importation into the EnSite mapping system. A detailed multi-surface geometry (NavX map) was collected by navigating a mapping catheter in target LA and PVs. Using a novel developmental registration algorithm the map was registered to LA/PV CT volume. Validation was performed using the registered 3D CT model for the guidance of ablation at the location of multiple implanted radio-opaque markers. Results: A total of 39 radio-opaque markers were implanted before CT including 9 LSPV, 8 RSPV, 7 RIPV, 9 LIPV, 3 roof, and 3 LAA locations. Subsequent registration of individual NavX maps to acquired 3D CT volume was successfully completed in all animals. RF ablations were performed at the predicted 3D registered model locations of the radio-opaque markers using 5 mm tip RF ablation catheter. Resulting mean lesion size was 5.3 x 6.5 mm. The lesions enveloped the point of marker attachment to the myocardium in 31/36 (86%) ablations. The average distance from the center of the RF lesion to the targeted site was 2.5 ± 1.5mm. 47 points were successfully navigated under fluorscopic and ICE guidance. All points were accurately portrayed on the 3D registered model. 3 points in the region of the RSPV floor did have minor offsets on the model due to technically difficult segmentation of the RSPV from the right pulmonary artery. Conclusion: These data demonstrate the feasibility of registering NavX derived geometries to CT data sets accommodating sources of cardiac, respiratory, and translational cycle dependent error. Catheter navigation precisely conducted using the registered model demonstrates accuracy within the range required for RF ablation.
Abstract 3119: Long-term Safety of Cilostazol in Patients With Peripheral Artery Disease
Hiatt, William R. , Brass, Eric P. , Money, Sam

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_699-b Get It

Cilostazol, a phosphodiesterase III inhibitor, is indicated to treat the symptoms of claudication in patients with peripheral arterial disease (PAD). At the time of approval the FDA required an additional long-term safety study to evaluate cilostazol’s effect on mortality. Subjects (n=1899) with a clinical diagnosis of PAD and symptoms of claudication were screened for a randomized, double blinded, placebo-controlled safety study of cilostazol. The modified intent-to-treat (mITT) population (n=1435) included all randomized patients who received at least one dose of study medication and includes follow up of more than 30 days after discontinuation of study drug. A total of 717 patients received cilostazol and 718 received placebo. Cilostazol was administered at a primary dose of 100 mg twice daily. Long-term adherence to study medication was poor with over 60% of participants discontinuing therapy by 36 months. Therefore the mortality analysis focused on deaths during the period on-treatment defined as the period during which study drug was taken plus a 30-day post-dosing follow up period. Total patient-years exposure on-treatment for cilostazol was 1046 and on placebo was 1090. On-treatment there were 18 deaths on cilostazol and 19 deaths on placebo for a hazard ratio of 0.99 (95% confidence interval 0.52 to 1.88). Cardiovascular deaths on-treatment occurred in 14 patients on cilostazol and 14 on placebo. In the full mITT population at 36 months, there were 101 deaths, 49 on cilostazol and 52 on placebo with hazard ratio of 0.94 (0.64 –1.39). Thus most deaths occurred more than 30 days after study drug discontinuation. Serious bleeding events affected 18 patients on cilostazol and 22 on placebo in the on-treatment population. Bleeding events were similar in patients also taking aspirin, aspirin plus clopidogrel or anticoagulants over the course of the study. This long-term study demonstrated no safety signal for cilostazol on all cause or cardiovascular mortality. However the study was under-powered to detect a small adverse impact of cilostazol on mortality (hazard ratio upper bound of the 95% confidence interval 1.88 in the on-treatment population). Serious bleeding events appeared not to be increased by cilostazol.
Abstract 2750: Multi-detector Computed Tomography Is An Accurate Screening Imaging Modality For Detection Of Thrombus In Patients Undergoing Catheter Ablation Of Atrial Fibrillation
Martinez, Matthew W. , Kirsch, Jacobo , Williamson, Eric E. , Cha, Yong‐Mei , Friedman, Paul A. , Ommen, Steve R. , Callahan, Mark J., Syed, Imran S., Feng, DaLi, Beinborn, Douglas S., Packer, Douglas L. , Brady, Peter A. , Asirvatham, Samuel J.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_610-b Get It

Introduction Multi-detector computed tomography (MDCT) is commonly used to identify pulmonary vein and left atrial anatomy prior to catheter ablation for atrial fibrillation (CAAF). Additionally, transesophageal echocardiography (TEE) is utilized to exclude left atrial/left atrial appendage thrombus (ICT). Whether MDCT alone can be used to exclude thrombus obviating the need for TEE is unknown. Methods All Pts referred for CAAF at Mayo Clinic between March 2004 and October 2006 were included. Clinical data (including CHADS score), 64 slice MDCT (non-ECG gated), TEE and intra-cardiac echocardiograph (ICE) were all performed and recorded. Image data was reviewed independently and blinded. The left atrial appendage (LAA) was defined as fully opacified or underfilled. An underfilled LAA was further interrogated using a region of interest over the filling defect and mean attenuation in Hounsfield Units (HU) were recorded. Results In total 400 Pts (mean age 56 ± 10 yrs; 76% male; EF 56 ± 10 % ) were included. 362 had no ICT by TEE nor filling defect by MDCT. 38 patients had an underfilled LAA in whom ICT was confirmed by TEE in 7. Sensitivity and specificity of MDCT for ICT was 100% and 92% respectively with a NPV of 100%. In 19 Pts with underfilled LAA’s, a mean LAA emptying velocity was found to be significantly reduced at 26 cm/s (6 – 61 cm/s). Those with a thrombus had a mean attenuation value below 70 HU. CHADS2 score was higher (2.0 versus 1.0) in Pts with LAA filling defect versus those without LAA filling defect. All Pts with confirmed thrombus were taking Warfarin. ICT was not seen in any Pts aged <52 yrs with CHADS score ≤1. Conclusions Sensitivity and specificity of MDCT for detection of LAA thrombus is high. LAA filling defects on MDCT correlate with low emptying velocities by TEE and low attenuation value in HU. These data would suggest that in the absence of MDCT filling defect, no further imaging is required. TEE should be utilized prior to CAAF to investigate MDCT filling defects. Multidetector Computed Tomography for the Detection of LAA Thrombus
Abstract 6023: The Need for Blood Transfusion Is an Independent Predictor of Incident Cardiovascular Events and All-Cause Mortality among Patients Undergoing Percutaneous Coronary Intervention
Mercado, Nestor, Dixon, Simon, Lamos, Pedro, Guarneri, Mimi, Terstein, Paul, Wijns, Williom, Boersma, Eric , Brugts, Jasper Jan , Ix, Joachim H. , Shlipak, Michael G. , Gersh, Bernard J. , O’Neill, William W.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 118 | Issue: suppl_18 | Pages: No page available

10.1161/circ.118.suppl_18.s_1049-a Get It

Periprocedural bleeding is one of the most frequent complications of percutaneours coronary interventions. We assessed the relation between blood transfusion and all-cause mortality or incident cardiovascular events (death, MI, stroke) among 6103 patients of the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events (EXCITE)-trial. Subjects were followed for 7 months after enrollment for the occurrence of events. Multivariate Cox-regression analysis evaluated the independent association of blood transfusion with each outcome adjusted for age, gender, race, diabetes mellitus, hypertension, hypercholesterolemia, history of MI, PCI, CABG, heart failure, LVEF<30%, use of beta-blockers, statins, ACE-inhibitors, platelet inhibitors and allocation to treatment with xemolifiban. In addition, propensity score analyses were performed (ROC 0.80). Mean age was 59.2 years, 21.7% were female, and 18.9% had diabetes mellitus. Of the169 patients who received blood transfusion, 14 (8.3%) died and 42 (24.9%) experienced a CVD event. Of the 5934 patients without transfusion, 65 (1.1%) died (p-value: <0.001) and 555 (9,4%) experienced a CVD event (p-value: <0.001) In multivariate analysis, blood transfusion was associated with a 5.3 fold increased risk of mortality (HR 5.3; 95% CI 2.8 –10.2), and a 2.5 fold increased risk of incident CVD (HR 2.5; 95% CI 1.7–3.4.) Noteworthy, patients who were US citizens had a higher transfusion rate then non-US citizens (OR 1.45, 95%CI 1.02–2.06) The need of blood transfusion is a strong and independent predictor of all-cause mortality and incident CVD events among patients undergoing PCI.
Abstract 5932: The Differences of Echocardiography and MRI Findings in Patients with Constrictive Pericarditis According to the History of Chest Radiation
Feng, DaLi, Glockner, James F., Martinez, Matthew W. , Edwards, William D. , Syed, Imran S., Araoz, Philip A. , Julsrud, Paul R., Bree, Jerome F, Williamson, Eric E. , Oh, Jae K. , Kim, Kye Hun

Mayo Clinic

Circulation | July 3, 2021 | Volume: 118 | Issue: suppl_18 | Pages: No page available

10.1161/circ.118.suppl_18.s_1032-c Get It

Background: Radiation therapy (RT) to the chest may induce various combined cardiac problems such as constrictive pericarditis (CP), restrictive myocardial disease, and coronary artery disease. Therefore, it was hypothesized that the MRI and transthoracic echocardiographic (TTE) findings in patients with CP may differ according to the history of RT. Methods: A total of 68 patients with CP who performed both TTE and MRI study at Mayo Clinic from 2002 to 2008 were reviewed and divided into two groups according to the history of RT; RT group (group I, n=13, 53.6±9.8 years, 8 males) versus no RT group (group II, n=55, 59.0±14.8, 45 males). Results: The results of TTE study were summarized in table . Early diastolic velocity of septal mitral annulus (E′) and deceleration time (DT) of mitral inflow was significantly lower, and the ratio of early diastolic mitral inflow velocity (E) to E′ is significantly higher in group I than in group II. Left atrial volume index (LAVI) was significantly lower and LA area and left ventricular end-diastolic dimension (LVEDD) was significantly smaller in group I than in group II. Delayed enhancement of pericardium was the only significant finding in MRI and significantly prevalent in group I than in group II (100.0% in group I vs 63.6% in group II, p=0.012). The other MRI findings including pericardial thickness, left ventricular and right ventricular ejection fraction, and the presence of pericardial and pleural effusion were not different between the groups. Conclusion: In CP patients with the history of RT compared to patients without history of RT, E′ and DT was significantly lower, LAVI and LVEDD were smaller, pericardial DE in MRI was invariably found. The lower E′ velocity and decreased chamber size and volumes may be explained by RT induced coexisting myocardial disease. TTE findings of the patients